Helen Tayton-Martin
2017
In 2017, Helen Tayton-Martin earned a total compensation of $1.4M as Chief Business Officer at Adaptimmune Therapeutics, a 30% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $163,925 |
|---|---|
| Option Awards | $849,927 |
| Salary | $364,279 |
| Other | $19,481 |
| Total | $1,397,613 |
Tayton-Martin received $849.9K in option awards, accounting for 61% of the total pay in 2017.
Tayton-Martin also received $163.9K in non-equity incentive plan, $364.3K in salary and $19.5K in other compensation.
Rankings
In 2017, Helen Tayton-Martin's compensation ranked 7,336th out of 14,666 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 50.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,336 out of 14,666 | 50th |
Division Manufacturing | 2,731 out of 5,772 | 53rd |
Major group Chemicals And Allied Products | 888 out of 2,075 | 57th |
Industry group Drugs | 695 out of 1,731 | 60th |
Industry Biological Products, Except Diagnostic Substances | 131 out of 313 | 58th |
Source: SEC filing on March 15, 2019.
Tayton-Martin's colleagues
We found four more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2017.